Canada
Founded in 2016 and headquartered in Canada, JVPLabs aims to revolutionize Congestive Heart Failure (CHF) management with its non-invasive assessment of the Jugular Venous Pressure. The company's flagship product, the JVPHome, offers comprehensive remote patient monitoring, allowing for the automated and non-invasive measurement of right-sided cardiac pressures, along with additional vital signs. This innovation facilitates hospital-quality monitoring across the continuum of care and empowers clinical care teams to optimize care for CHF patients, ultimately keeping them feeling well and out of the hospital.
The company recently secured a Seed Round investment at 01 January 2023 from the Archangel Network of Funds. With an impressive leadership team boasting a strong track record and multiple successful exits, JVPLabs has garnered support from cardiologists in the US, Canada, and the UK, who have expressed interest in including the device in their trials. This endorsement, coupled with the device's 80% improvement over current practices and its proven usability in elderly patient populations, bolsters JVPLabs' positioning in the market.
By addressing a crucial need in CHF management and garnering support from reputable investors and healthcare professionals, JVPLabs presents a compelling investment opportunity in the health care and manufacturing industries.
